Another financing vehicle is being utilized by small-cap healthcare companies: the Standby Equity Distribution Agreement (SEDA). This relatively new “mechanism” is another … alternative to Read more…
In today’s capital markets; this old but new (usage) capital-raising rage has many small-cap healthcare companies filling their coffers after finding that
The stock market and overall economy are still depreciated; but, this sector is holding up better as there are signs that
I get calls and e-mails re where to begin, whether one should invest, what should be bought and I state
Investors are now asking more questions about the short, near and long term viability of healthcare stocks. In a slowly rebounding market, despite today’s volatility; there is a silver lining; smaller, leaner healthcare companies are emerging stronger from the past crisis.
There is no quick fix … Read more…
Scientists, managements and investors get excited by a candidate compound’s potential; but
Every time the markets rebound, investors deliberate whether this marks the bottom for share pricing and if so, might it be time to get in. However, for those of us who remain skeptical; we have seen too many spikes in momentum, resistance, confidence and resilience as second quarter earnings were good but will it last? Valuations provide indicators when compared to the rapid decline and slow moves to present market levels.
The ongoing economic crisis had made bankruptcies; one of the newest “EXIT” strategies for many emerging small cap healthcare companies. The companies most at risk have less than 6 months of cash and usually no “definitive” clinical data in the near future. It has been stated that 25% of emerging small cap healthcare companies (usually biotechs) fall into this category of teetering on the edge. Is one of the issues the plethora of “me to” platforms?
Blogging is reshaping the web impacting the dissemination of new conviction ideas. It is shaking up markets and journalism enabling millions of people to have a voice and connect with others. I blog to add commentary, update news flow and insightful opinions that are intelligent, fit – to print and SEC – compliant. Wall Street has dramatically slashed its ranks of analysts providing research but, scientific platforms and industry sectors need to be better researched for conviction ideas. As an industry veteran, I am continually mortified about the gross inaccuracies of message boards that deal with fiction, inaccurate prognostications and rants. The role of my internet blogging, I believe increases transparency.
Biopure – the Cambridge based biotechnology company – founded in 1984 (NASDAQ: BPUR) filed for Chapter 11 (7/16/09). Biopure developed pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body’s tissues. BPUR failed amid numerous regulatory setbacks – and should have known – then – there are no magic acts in this business! BPUR has now entered into an agreement with OPK Biotech LLC for the sale of all of its assets. Note, if the proposed OPK Biotech LLC transaction closes (as stated) there will be limited, if any, value for the common stockholders in the bankruptcy liquidation process – the filing lists total assets of $5.06 M and total debts of $2.72 M.
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.